19/03/2026
Presenting New Data at AD/PD for Alzheimer’s project NeuroRestore
- Just published the material. - Download it.
AlzeCure Pharma is today presenting new data for its Alzheimer’s project NeuroRestore ACD856 at the international Alzheimer's conference AD/PD 2026, taking place in Copenhagen, and have just published the material.
ACD856 is in preparation for phase 2 in patient’s with Alzheimer’s in a study which is co-funded by the European Innovation Council (EIC) through a grant.
“These new data with ACD856 show that the compound has a clear biological effect on NGF and BDNF signaling mediated by TRK receptors. These systems play an important role in the normal function of neurons in the brain, and improved signaling leads to positive effects in disturbed systems, such as improved memory function and antidepressant effects,” say Cristina Parrado-Fernández, Senior Scientist at AlzeCure.
The unique pharmacological mechanism of NeuroRestore also enables multiple indications, such as Alzheimer's and Parkinson's disease, but also depression. ACD856 is a first-in-class drug candidate for Alzheimer's disease.
The presentation is available on AlzeCure's website: https://www.alzecurepharma.se/en/presentations-and-interviews/
Read the full press release here: https://www.alzecurepharma.se/en/alzecure-presents-new-preclinical-data-with-neurorestore-acd856-at-the-alzheimers-conference-ad-pd/
AlzeCure Pharma Cristina Parrado Life Science Cluster Flemingsberg
